Key facts
- This page summarizes Flagship Ventures Fund V General Partner LLC's Form 4 filing for Codiak BioSciences, Inc..
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Sep 2022, 19:30.
Flagship Ventures Fund V General Partner LLC - 15 Sep 2022 Form 4 Insider Report for Codiak BioSciences, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 15 Sep 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Sep 2022, 19:30:18 UTC
- Next SEC filing
- 26 May 2023
- Source filing
- View source filing
- Reporting owner signature
- Flagship Ventures Fund V General Partner LLC, By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: Manager
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Flagship Ventures Fund V General Partner LLC filed Form 4 for Codiak BioSciences, Inc. on 16 Sep 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CDAKQ
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +722,590
- Change %
- +63%
- Price
- Shares after
- 1,865,767
- Date
- 15 Sep 2022
- Ownership
- By Flagship Ventures Fund V, L.P.
- Footnotes
- F1, F2
CDAKQ
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +210,743
- Change %
- +22%
- Price
- Shares after
- 1,188,920
- Date
- 15 Sep 2022
- Ownership
- By Flagship V VentureLabs Rx Fund, L.P.
- Footnotes
- F1, F3
CDAKQ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 485,949
- Date
- 15 Sep 2022
- Ownership
- Flagship VentureLabs V LLC
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDAKQ
transaction
Derivative
Warrants to purchase Common Stock
Purchase
- Transaction value
- Shares
- +722,590
- Change %
- Price
- Shares after
- 722,590
- Date
- 15 Sep 2022
- Ownership
- By Flagship Ventures Fund V, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 722,590
- Exercise price
- $1.88
- Footnotes
- F1, F2
CDAKQ
transaction
Derivative
Warrants to purchase Common Stock
Purchase
- Transaction value
- Shares
- +210,743
- Change %
- Price
- Shares after
- 210,743
- Date
- 15 Sep 2022
- Ownership
- By Flagship V VentureLabs Rx Fund, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 210,743
- Exercise price
- $1.88
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.
Footnote F2
Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Footnote F3
Shares held by Flagship Fund V Rx. Flagship V GP is the general partner of Flagship Fund V Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Footnote F4
Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.